The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing
Open accessAbstract
The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene), and reduced or absent activity of this enzyme can result in severe, and sometimes fatal, toxicity. We summarize evidence from the published literature supporting this association and provide dosing recommendations for fluoropyrimidines based on DPYD genotype (updates at http://www.pharmgkb.org).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network
Relling, M. V., & Klein, T. E. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.279 · Cited by 1,164
Self-citationPharmacogenetics: From Bench to Byte— An Update of Guidelines
Swen, J. J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-van der Zee, A. H., Mulder, H., Rongen, G. A. P. J. M., van Schaik, R. H. N., Schalekamp, T., Touw, D. J., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.34 · Cited by 1,018
Self-citationClinical Pharmacology of 5-Fluorouracil
Diasio, R. B., & Harris, B. E. (1989) · Clinical Pharmacokinetics · doi:10.2165/00003088-198916040-00002 · Cited by 969
Self-citationDiasio, R. B., Beavers, T. L., & Carpenter, J. T. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113308 · Cited by 503
Self-citationPopulation study of dihydropyrimidine dehydrogenase in cancer patients.
Etienne, M. C., Lagrange, J. L., Dassonville, O., Fleming, R., Thyss, A., Renée, N., Schneider, M., Demard, F., & Milano, G. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.11.2248 · Cited by 436
Schwab, M., Zanger, U. M., Marx, C., Schaeffeler, E., Klein, K., Dippon, J., Kerb, R., Blievernicht, J., Fischer, J., Hofmann, U., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4182 · Cited by 393
Self-citationKuilenburg, A. B. P., Haasjes, J., Richel, D. J., Zoetekouw, L., van LENTHE, H., ABREU, R. A. D., Maring, J. G., Vreken, P., & Gennip, A. H. (2000) · PubMed · Cited by 359
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.
Wei, X., McLeod, H. L., McMurrough, J., Gonzalez, F. J., & Fernandez-Salguero, P. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118830 · Cited by 356
Self-citationGamelin, E., Delva, R., Jacob, J., Merrouche, Y., Raoul, J. L., Pezet, D., Dorval, E., Piot, G., Morel, A., & Boisdron-Celle, M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.3934 · Cited by 346
Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
Milano, G., Etienne, M. C., Pierrefite, V, Barberi-Heyob, M., Deporte-Fety, R., & Renée, N. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690098 · Cited by 275
Morel, A., Boisdron-Celle, M., Fey, L., Soulie, P., Craipeau, M. C., Traore, S., & Gamelin, E. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0327 · Cited by 236
Fleming, R. A., Milano, G. A., Thyss, A., Étienne-Grimaldi, M.-C., Renée, N., Schneider, M., & Demard, F. (1992) · PubMed · Cited by 235
Dihydropyrimidine Dehydrogenase Gene as a Major Predictor of Severe 5-Fluorouracil Toxicity
Amstutz, U., Froehlich, T. K., & Largiadèr, C. R. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.72 · Cited by 217
Deenen, M. J., Tol, J., Burylo, A. M., Doodeman, V. D., de Boer, A., Vincent, A., Guchelaar, H.-J., Smits, P. H. M., Beijnen, J. H., Punt, C. J. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2209 · Cited by 191
Kuilenburg, A. B. P., Meinsma, R., Zoetekouw, L., & Gennip, A. H. (2002) · Pharmacogenetics · doi:10.1097/00008571-200210000-00007 · Cited by 178
PharmGKB summary: fluoropyrimidine pathways
Thorn, C. F., Marsh, S., Whirl‐Carrillo, M., McLeod, H. L., Klein, T. E., & Altman, R. B. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833c6107 · Cited by 142
Self-citationOffer, S. M., Wegner, N. J., Fossum, C. C., Wang, K., & Diasio, R. B. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3858 · Cited by 121
Self-citationJohnson, M. R., Wang, K., & Diasio, R. B. (2002) · PubMed · Cited by 120
Self-citationInborn errors of pyrimidine degradation: Clinical, biochemical and molecular aspects
Gennip, A. H., Abeling, N. G. G. M., Vreken, P., & Kuilenburg, A. B. P. (1997) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005356806329 · Cited by 112
Offer, S. M., Lee, A. M., Mattison, L. K., Fossum, C., Wegner, N. J., & Diasio, R. B. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.69 · Cited by 102
Self-citationCapitain, O., Boisdron‐Celle, M., Poirier, A.-L., Abadie‐Lacourtoisie, S., Morel, A., & Gamelin, E. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500476 · Cited by 101
PharmGKB summary: carbamazepine pathway
Thorn, C. F., Leckband, S. G., Kelsoe, J. R., Leeder, J. S., Müller, D. J., Klein, T. E., & Altman, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328348c6f2 · Cited by 99
Self-citationMaring, J. G., Kuilenburg, A. B. P., Haasjes, J., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600208 · Cited by 99
Yang, C. G., Ciccolini, J., Blesius, A., Dahan, L., Bagarry-Liegey, D., Brunet, C., Varoquaux, A. D., Frances, N., Marouani, H., Giovanni, A., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1282-4 · Cited by 81
Inborn errors of purine and pyrimidine metabolism
Jurecka, A. (2009) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-009-1094-z · Cited by 77
Hirota, T., Date, Y., Nishibatake, Y., Takane, H., Fukuoka, Y., Taniguchi, Y., Burioka, N., Shimizu, E., Nakamura, H., Otsubo, K., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2011.12.018 · Cited by 65
Groß, E., Ullrich, T., Seck, K., Müller, V., de Wit, M., von Schilling, C., Meindl, A., Schmitt, M., & Kiechle, M. B. (2003) · Human Mutation · doi:10.1002/humu.9201 · Cited by 63
Noguchi, T., Tanimoto, K., Shimokuni, T., Ukon, K., Tsujimoto, H., Fukushima, M., Noguchi, T., Kawahara, K., Hiyama, K., & Nishiyama, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0337 · Cited by 61
Cited by
Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers
Dunnenberger, H. M., Crews, K. R., Hoffman, J. M., Caudle, K. E., Broeckel, U., Howard, S. C., Hunkler, R. J., Klein, T. E., Evans, W. E., & Relling, M. V. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124835 · Cited by 511
Self-citationMeulendijks, D., Henricks, L. M., Sonke, G. S., Deenen, M. J., Froehlich, T. K., Amstutz, U., Largiadèr, C. R., Jennings, B. A., Marinaki, A. M., Sanderson, J. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00286-7 · Cited by 381
Self-citationClinically Actionable Genotypes Among 10,000 Patients With Preemptive Pharmacogenomic Testing
Van Driest, S., Shi, Y., Bowton, E., Schildcrout, J., Peterson, J., Pulley, J., Denny, J., & Roden, D. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.229 · Cited by 334
A Review of the Important Role of CYP2D6 in Pharmacogenomics
Taylor, C., Crosby, I., Yip, V., Maguire, P., Pirmohamed, M., & Turner, R. M. (2020) · Genes · doi:10.3390/genes11111295 · Cited by 316
Implementation and utilization of genetic testing in personalized medicine
Scott, S., Abul-Husn, N., Owusu Obeng, A., Sanderson, S., & Gottesman, O. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s48887 · Cited by 106
Metadata
- Authors
- Caudle, K. E., Thorn, C. F., Klein, T. E., Swen, J. J., McLeod, H. L., Diasio, R. B., & Schwab, M.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2013-08-29
- Volume
- 94
- Issue
- 6
- Pages
- 640-645
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2047544514
- Cited by
- 330
- References
- 28
- FWCI
- 43.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.